Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
12.17
-0.44 (-3.49%)
At close: Apr 28, 2026, 4:00 PM EDT
12.14
-0.03 (-0.25%)
After-hours: Apr 28, 2026, 7:33 PM EDT
Benitec Biopharma Employees
Benitec Biopharma had 19 employees as of June 30, 2025. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$2,321,474
Market Cap
416.88M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Neurogene | 131 |
| Invivyd | 122 |
| Aura Biosciences | 113 |
| Prelude Therapeutics | 79 |
| Assembly Biosciences | 73 |
| Lexeo Therapeutics | 59 |
| PureTech Health | 56 |
BNTC News
- 14 hours ago - Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 7 weeks ago - Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) - GlobeNewsWire
- 3 months ago - Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response - GlobeNewsWire
- 5 months ago - Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 6 months ago - Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - GlobeNewsWire
- 6 months ago - Benitec Biopharma Inc. Announces Proposed Public Offering - GlobeNewsWire
- 6 months ago - Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - GlobeNewsWire
- 6 months ago - Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewsWire